PSMA4在肺腺癌预后、诊断和免疫浸润中的作用和机制研究

赵静; 李艳梅; 王雪樾; 聂恬; 王洁; 翁启明; 张静; 范晔

doi:10.16016/j.2097-0927.202405037

您当前的位置：

首页 >

文章列表页 >

PSMA4在肺腺癌预后、诊断和免疫浸润中的作用和机制研究

临床医学 | 更新时间：2026-01-09

- PSMA4在肺腺癌预后、诊断和免疫浸润中的作用和机制研究
- Role and mechanism of PSMA4 in prognosis, diagnosis and immune infiltration of lung adenocarcinoma
- 陆军军医大学学报 2024年46卷第17期页码：1985-1993
- 作者机构：
  
  1.400037 重庆，陆军军医大学(第三军医大学)第二附属医院：临床技能培训中心
  2.610083 成都，中国人民解放军西部战区总医院检验科
  3.850000 拉萨，中国人民解放军西藏军区总医院儿科
  4.610072 成都，四川省人民医院消化内镜中心
  5.400037 重庆，陆军军医大学(第三军医大学)第二附属医院：野战内科研究所
  6.400037 重庆，陆军军医大学(第三军医大学)第二附属医院：呼吸科
- 作者简介：
  
  [张静，E-mail：83728087@qq.com ZHANG Jing, E-mail: 83728087@qq.com
  [范晔，E-mail：fygan@163.com FAN Ye, E-mail: fygan@163.com
- 基金信息：
  
  重庆市科卫联合项目(2023QNXM010)
- DOI：10.16016/j.2097-0927.202405037
  中图分类号： R394.3;R730.23;R734.2
- 收稿：2024-05-13，
  
  修回：2024-06-29，
  
  纸质出版：2024-09-15
- 稿件说明：
移动端阅览
赵静, 李艳梅, 王雪樾, 等. PSMA4在肺腺癌预后、诊断和免疫浸润中的作用和机制研究[J]. 陆军军医大学学报, 2024,46(17):1985-1993.

Jing ZHAO, Yanmei LI, Xueyue WANG, et al. Role and mechanism of PSMA4 in prognosis, diagnosis and immune infiltration of lung adenocarcinoma[J]. Journal of Army Medical University, 2024, 46(17): 1985-1993.
赵静, 李艳梅, 王雪樾, 等. PSMA4在肺腺癌预后、诊断和免疫浸润中的作用和机制研究[J]. 陆军军医大学学报, 2024,46(17):1985-1993. DOI： 10.16016/j.2097-0927.202405037.

Jing ZHAO, Yanmei LI, Xueyue WANG, et al. Role and mechanism of PSMA4 in prognosis, diagnosis and immune infiltration of lung adenocarcinoma[J]. Journal of Army Medical University, 2024, 46(17): 1985-1993. DOI： 10.16016/j.2097-0927.202405037.

摘要

目的

探究PSMA4在肺腺癌(lung adenocarcinoma

LUAD)预后、诊断和免疫浸润中的作用和机制。

方法

从癌症基因组图谱(the cancer genome atlas

TCGA)数据库中获取LUAD患者的表达谱和临床信息。通过Wilcoxon秩和检验比较LUAD组(

=539)与正常组(

=59)PSMA4基因的表达水平。通过在GEO数据库下载GSE40791和GSE10072 LUAD数据集，验证PSMA4在LUAD组与正常组中的表达水平。收集10对2023年1-12月在陆军军医大学第二附属医院呼吸科进行纤维支气管镜肺活检术的LUAD患者的肿瘤和癌旁组织样本。采用RT-qPCR技术验证PSMA4在10对LUAD和癌旁组织中的表达。体外培养肺癌细胞和正常肺上皮细胞，通过RT-qPCR检测PSMA4在各组细胞中的表达。并对PSMA4的高低表达组进行了功能富集分析和免疫细胞浸润分析，通过Cox回归分析和Kaplan-Meier (KM)法确定PSMA4对于LUAD的诊断和预后的价值，并构建列线图预测不同时间点的总生存率。

结果

TCGA数据集、GSE40791和GSE10072 LUAD数据集中的表达数据显示，PSMA4在LUAD组中的表达明显高于正常组(

＜0.01)。RT-qPCR检测分析发现，PSMA4在LUAD和肺癌细胞中的表达显著高于癌旁组织和正常肺上皮细胞(

＜0.01)。PSMA4高表达是诊断LUAD和预后不良的标志物，与肿瘤微环境中效应记忆性T细胞、滤泡辅助性T细胞、B淋巴细胞、自然杀伤细胞、中央记忆性T细胞、肥大细胞的水平的降低有关。

结论

PSMA4对LUAD有良好的诊断效能，并且与LUAD的预后和免疫浸润密切相关。

Abstract

Objective

To investigate the role of PSMA4 in the prognosis

diagnosis and immune infiltration of lung adenocarcinoma (LUAD)

and explore its underlying mechanism.

Methods

The expression profiles and clinical data of LUAD patients were sourced from the Cancer Genome Atlas (TCGA) database. The expression level of PSMA4 in LUAD tissues (

=539) and normal tissues (

=59) were compared using the Wilcoxon rank-sum test. The expression levels of PSMA4 in LUAD tissues and normal tissues were validated by analyzing the GSE40791 and GSE10072 LUAD datasets obtained from the Gene Expression Omnibus (GEO) database. In addition

tumor and adjacent non-cancerous tissues were collected from 10 LUAD undergoing lung biopsy by fiberoptic bronchoscopy in Second Affiliated Hospital of Army Medical University from January to December 2023. The PSMA4 expression in above samples was further verified using RT-qPCR. RT-qPCR was performed to detect the expression of PSMA4 in lung cancer cells and normal lung epithelial cells. Functional enrichment analysis and immune cell infiltration analysis were conducted on the cells with high and low expression of PSMA4. Cox regression analysis and Kaplan-Meier (KM) survival analysis were used to determine the diagnostic and prognostic value of PSMA4 for LUAD

and a nomogram was constructed to predict the overall survival rate at different time points.

Results

The analysis of TCGA datasets

GSE40791

and GSE10072 LUAD data revealed that PSMA4 expression was significantly higher in LUAD tissues than in normal tissues (

0.01). RT-qPCR further confirmed that the expression of PSMA4 was obviously elevated in LUAD tissues and lung cancer cells than adjacent non-cancerous tissues and normal lung epithelial cells (

0.01). High PSMA4 expression could be regarded as a marker for LUAD diagnosis and poor prognosis

and was associated with reduced proportions of Tem cells

TFH cells

B cells

NK cells

Tcm cells

and mast cells in the tumor microenvironment.

Conclusion

PSMA4 presents significant diagnostic performance for LUAD

and is closely associated with the prognosis and immune infiltration of this malignancy.

关键词

Keywords

references

SHI Q, JU J G. Circ_0001998regulates the proliferation, invasion, and apoptosis of lung adenocarcinoma via sponging miR-145[J]. Evid Based Complement Alternat Med, 2022, 2022: 6446150. DOI: 10.1155/2022/6446150.

EDITORIAL OFFICE. Erratum to identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance[J]. Transl Lung Cancer Res, 2022, 11(8): 1731-1733. DOI: 10.21037/tlcr-2022-4.

LU J, TANG H T, YANG X G, et al . Diagnostic value and imaging features of multi-detector CT in lung adenocarcinoma with ground glass nodule patients[J ] . Oncol Lett, 2020, 20(1): 693-698. DOI: 10.3892/ol.2020.11631.

MERAE ALSHAHRANI M. A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers[J]. Saudi J Biol Sci, 2022, 29(4): 2072-2084. DOI: 10.1016/j.sjbs.2022.01.017.

KWON D H, EOM G H, KO J H, et al . MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification[J ] . Nat Commun, 2016, 7: 10492. DOI: 10.1038/ncomms10492.

WATCHARANURAK P, MUTIRANGURA A, AKSORNKITTI V, et al . The high FKBP1A expression in WBCs as a potential screening biomarker forpancreatic cancer[J ] . Sci Rep, 2024, 14(1): 7888. DOI: 10.1038/s41598-0 24-58324-z.

CHIAO CC, LIU Y H, PHAN N N, et al . Prognostic and genomic analysis of proteasome 20S subunit alpha (PSMA) family members in breast cancer[J ] . Diagnostics, 2021, 11(12): 2220. DOI: 10.3390/diagnostics11122220.

LI M M, WU L. Functional analysis of keratinocyte and fibroblast gene expression in skin and keloid scar tissue based on deviation analysis of dynamic capabilities[J]. Exp Ther Med, 2016, 12(6): 3633-3641. DOI: 10.3892/etm.2016.3817.

KO Y H, WON H S, JEON E K, et al . Prognostic significance of CD44s expression in resected non-small cell lung cancer[J ] . BMC Cancer, 2011, 11: 340. DOI: 10.1186/1471-2407-11-340.

GENG Y M, MEI Y L, XI Y, et al . Bilirubin can be used as a prognostic factor for lung adenocarcinoma patients with EGFR mutations[J ] . Onco Targets Ther, 2020, 13: 11089-11095. DOI: 10.2147/OTT.S266477.

MAZZOCCHI A, DEVARASETTY M, HERBERG S, et al . Pleural effusion aspirate for use in 3D lung cancer modeling and chemotherapy screening[J ] . ACS Biomater Sci Eng, 2019, 5(4): 1937-1943. DOI: 10.1021/acsbiomaterials.8b01356.

DING X Q, WANG Z Y, XIA D, et al . Proteomic profiling of serum exosomes from patients with metastatic gastric cancer[J ] . Front Oncol, 2020, 10: 1113. DOI: 10.3389/fonc.2020.01113.

XIONG Q H, FENG R, FISCHER S, et al . Proteasomes of autophagy-deficient cells exhibit alterations in regulatory proteins and a marked reduction in activity[J ] . Cells, 2023, 12(11): 1514. DOI: 10.3390/cells12111514.

BAI Y S, ZHENG J, CHENG L, et al . Potentially functional genetic variants of VAV2 and PSMA4 in the immune-activation pathway and non-small cell lung cancer survival[J ] . J Gene Med, 2022, 24(10): e3447. DOI: 10.1002/jgm.3447.

VALIEVA M E, ARMEEV G A, KUDRYASHOVA K S, et al . Large-scale ATP-independent nucleosome unfolding by a histone chaperone[J ] . Nat Struct Mol Biol, 2016, 23(12): 1111-1116. DOI: 10.1038/nsmb.3321.

HSU M T, WANG Y K, TSENG Y J. Exosomal proteins and lipids as potential biomarkers for lung cancer diagnosis, prognosis, and treatment[J]. Cancers, 2022, 14(3): 732. DOI: 10.3390/cancers14030732.

LIU W, YOU W H, LAN Z W, et al . An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoi d structure[J ] . Cell Rep Med, 2024, 5(3): 101448. DOI: 10.1016/j.xcrm.2024.101448.

LEE I H, WANG H Y, CHEN YY, et al . Synergistic B and T lymphocyte interaction: prognostic implications in non-small cell lung cancer[J ] . Am J Cancer Res, 2024, 14(3): 1227-1242. DOI: 10.62347/TDIV2436.

CUI Y N, CHEN Y P, ZHAO P Y, et al . Peripheral NK cells identified as the predictor of response in extensive-stage small cell lung cancer patients treated with first-line immunotherapy plus chemotherapy[J ] . Clin Transl Oncol, 2024: online ahead of print. DOI: 10.1007/s12094-024-03479-4.

TANG X, LUO X R, WANG X, et al . Chrysin inhibits TAMs-mediated autophagy activation via CDK1/ULK1 pathway and reverses TAMs-mediated growth-promoting effects in non-small cell lung cancer[J ] . Pharmaceuticals, 2024, 17(4): 515. DOI: 10.3390/ph17040515..

SCHAD F, THRONICKE A, HOFHEINZ R D, et al . Patients with advanced or metastasised non-small-cell lung cancer with Viscum album L. therapy in addition to PD-1/PD-L1 blockade: a real-world data study[J ] . Cancers, 2024, 16(8): 1609. DOI: 10.3390/cancers16081609..

浏览量

132

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

肺腺癌相关tsRNA的筛选和验证

腺苷脱氨酶1在肺腺癌组织中的表达及临床意义

131例婴幼儿期自发性颅内出血临床分析

儿童全结肠无神经节细胞症的临床分析

长链非编码RNA SFTA1P在肺腺癌中的表达及预后预测研究